[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [Risk](https://github.com/mm80843/T3.5/tree/pages/docs/Risk/index.md) >> Individual ID:PBN__Risk_18053 

# __Absence of covid-19 treatment and delayed availability of vaccine__

## Articles mentionning the risk

* [Mesa_vieira_covid-19_2020](https://github.com/mm80843/T3.5/blob/pages/Article/PBN__Article_644.md)

## Mitigations of this risk

* [Research and development of antiviral treatments, vaccine development, and nonpharmacological practices](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_20017.md)

## Name of the risk

Continued high rates of infection and significant health burden

## People affected by this risk

* [Especially those at higher risk](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_9.md)
* [General population](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_5494.md)

## Stakeholders who can mitigate this risk

* [Government](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_73.md)
* [Pharmaceutical companies](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_413.md)
* [Research institutions](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_124.md)

## Technologies linked to the risk

* [And nonpharmacological prevention strategies](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_835.md)
* [Antiviral therapies](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_20382.md)
* [Vaccine development](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_20383.md)

## This Risk belongs to this RiskGroup

* [Public health risks](https://github.com/mm80843/T3.5/blob/pages/RiskGroup/PBN__RiskGroup_3.md)

## This Risk belongs to this RiskSubgroup

* [Lack of effective medical solutions](https://github.com/mm80843/T3.5/blob/pages/RiskSubgroup/PBN__RiskSubgroup_37.md)

